

# **CNIO Frontiers Meetings**

## **Molecular Cancer Therapeutics**

Madrid, March 8-10, 2010

### **Organisers**

**S. Gail Eckhardt**, University of Colorado Denver, Aurora, USA  
**Roy S. Herbst**, The University of Texas MD Anderson Cancer Center, Houston, USA  
**Manuel Hidalgo**, CNIO, Madrid, Spain

**MONDAY, MARCH 8<sup>th</sup>**

9:00-9:15 **Welcome address**

**Manuel Hidalgo**, CNIO, Madrid, Spain

### **Session I: Emerging new cancer targets and drugs**

**Chair: Roy S. Herbst**

9:15-9:50 **Douglas Yee**, University of Minnesota, Minneapolis, USA  
*"Insulin growth factor receptor 1 inhibitors"*

9:50-10:25 **Alex Adjei**, Roswell Park Cancer Institute, Buffalo, USA  
*"Targeting the Ras-Raf-MEK for cancer treatment"*

10:25-11:00 **Patricia LoRusso**, The Barbara Ann Karmanos Cancer Institute, Detroit, USA  
*"Therapeutics targeting the c-Met pathway"*

11:00-11:40 *Coffee break and poster session*

11:40-12:15 **Josep Taberero**, Vall d'Hebron University Hospital, Barcelona, Spain  
*"Inhibitors of the PI3K-Akt pathway"*

12:15-12:50 **S. Gail Eckhardt**, University of Colorado Denver, Aurora, USA  
*"PAK-4, a novel cancer target"*

12:50-14:20 *Lunch and poster session*

### **Session II: Lessons learned from recent successfully developed new agents**

**Chair: Alex Adjei**

14:20-14:55 **Jaap Verweij**, Erasmus University Medical Center, Rotterdam, The Netherlands  
*"Clinical development of imatinib mesylate"*

14:55-15:30 **Gary Clark**, Array Biopharma, Boulder, USA  
*"Erlotinib: Strategies for a successful clinical development"*

- 15:30-16:05 **Eric Rowinsky**, Imclone Systems, New York, USA  
***“Cetuximab: An example of implementing biomarkers in clinical research”***
- 16:05-16:40 **Manuel Hidalgo**, CNIO, Madrid, Spain  
***“Pathway to approval for mTOR inhibitors: Luck or rationale?”***
- 16:40-17:10 *Coffee break and poster session*
- 17:10-18:00 **Key note address**  
**Chair: S. Gail Eckhardt**
- Neal Rosen**, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, USA  
***“Targeting oncogene addition”***

**TUESDAY, MARCH 9<sup>th</sup>**

**Session III: Innovation in clinical trials design**

**Chair: Josep Tabernero**

- 8:50-9:25      **Elizabeth Garrett**, Medical University of South Carolina, Charleston, USA  
*“Innovative trial designs for dose finding studies”*
- 9:25-10:00    **Lillian Siu**, Ontario Cancer Institute, Toronto, Canada  
*“Novel phase II clinical trials”*
- 10:00-10:35   **Emiliano Calvo**, Centro Oncológico Clara Campal, Madrid, Spain  
*“Strategies to combine molecular targeted agents in the clinic”*
- 10:35-11:10   **Lajos Pusztai**, University of Texas MD Anderson Cancer Center, Houston, USA  
*“Title pending”*
- 11:10-11:40   *Group picture, coffee break and poster session*

**Sesion IV: Emerging new anticancer agents**

**Chair: Lillian Siu**

- 11:40-12:15   **Charles Rudin**, The Johns Hopkins University, Baltimore, USA  
*“The Hedgehog signalling pathway for cancer therapeutics”*
- 12:15-12:50   **Johann de Bono**, Institute of Cancer Research and Royal Marsden NHS  
Foundation Trust, Sutton, UK  
*“PARP inhibitors”*
- 12:50-13:25   **Adrian Senderowicz**, AstraZeneca, Philadelphia, USA  
*“Cell cycle inhibitors”*
- 13:25-15:00   *Lunch and poster session*

**Session V: Short talks from selected posters**

**Chair: Elizabeth Garrett**

- 15:00-15:20   Short talk # 1
- 15:20-15:40   Short talk # 2
- 15:40-16:00   Short talk # 3
- 16:00-16:40   *Coffee break and poster session*
- 16:40-17:30   **Key note address**  
**Chair: Manuel Hidalgo**

**Dan Von Hoff**, Translational Genomics Research Institute, Phoenix, USA  
*“Personalising cancer drug development”*

**WEDNESDAY, MARCH 10<sup>th</sup>**

**Session VI: Applying biomarkers to clinical cancer research**

**Chair: Emiliano Calvo**

- 9:10-9:45      **Roy S. Herbst**, The University of Texas MD Anderson Cancer Center, Houston, USA  
*“Strategies to implement predictive biomarkers in clinical trials”*
- 09:45-10:20    **Antonio Jimeno**, The University of Colorado Denver, Aurora, USA  
*“Pharmacodynamic studies in anticancer drug development”*
- 10:20-10:55    **Richard Wahl**, The Johns Hopkins PET Center, Baltimore, USA  
*“Functional imaging in drug development”*

**10:55 Closing remarks and poster prize**

**Roy S. Herbsts**, The University of Texas MD Anderson Cancer Center, Houston, USA  
**S. Gail Eckhardt**, University of Colorado Denver, Aurora, USA

**Note:** Talks: 25 minutes / Short talk: 15 minutes / Key note: 40 minutes

**Discussion:** 10 minutes after each talk / 5 minutes after each short talk / 10 minutes after each key note